Seoul [South Korea], May 12 (ANI/Global Economic): NeoImmuneTech said on the 11th that it has obtained the approval for a phase 2 clinical trial plan that concomitant administration of US Merck's immune checkpoint inhibitor Keytruda and its T-cell amplifier NT-I7 to patients with glioblastoma from the United States Food & Drug Administration (US FDA).

The phase 2 trial will be led by Professor Jian Campian at the US Mayo Clinic. It will evaluate the safety and treatment efficacy. Merck and NeoImmuneTech will supply Keytruda and NT-I7.

Also Read | China-Pakistan Economic Corridor: ‘Pakistan Committed to Fast-Tracking Key CPEC Projects’, Says Foreign Minister Bilawal Bhutto.

The research team expects the concomitant administration of Keytruda and NT-I7 to improve the survival rate of patients with glioblastoma.

The survival time of glioblastoma is less than 6 months, and the prognosis is very poor. Some chemotherapy drugs and a target anticancer Avastin are used for treatment, but the effectiveness is not significant. Genexine is conducting a clinical trial of the concomitant administration of Avastin and Efineptakin Alfa (GX-I7) in Korea, and NeoImmuneTech plans to test immune checkpoint inhibitor and T-cell amplifier. After the phase 2 trial, it will enter the phase 3 trial of the most likely treatment.

Also Read | China's Tibet Airlines Plane With 122 People Veers off Runway, Catches Fire in Chongqing City; Over 40 Injured (Watch Video).

NT-I7 is a drug that amplifies T cell immunity to remove cancer cells and infected cells. Currently, it is under clinical development to treat various deadliest cancers and infectious diseases. (ANI/Global Economic)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)